The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV 'seroreversion'

Autor: MV Ragni, OK Ndimbie, EO Rice, FA Bontempo, S Nedjar

Publikováno v: Blood. 82(3)

Hepatitis C virus (HCV) is a major cause of transfusion-induced chronic liver disease in hemophiliacs, with 70% to 90% being anti-HCV positive. Seroreversion or loss of antibody response to HCV has been observed in a small proportion of human immunod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d4088a88e424818bb077a80891d1021
https://pubmed.ncbi.nlm.nih.gov/7687887

1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B

Autor: MV Ragni, A Winkelstein, L Kingsley, JA Spero, JH Lewis

Publikováno v: Blood. 70(3)

A cohort of 181 patients with hemophilia A (149) and hemophilia B (32) cared for at the Hemophilia Center of Western Pennsylvania was followed to determine human immunodeficiency virus (HIV) seroprevalence, seroconversion rate, and clinical and immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9dd37210296fd76519469776e1b5ee
https://pubmed.ncbi.nlm.nih.gov/2887224

Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk.

Autor: Vir P; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA., Gunasekera D; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA., Dorjbal B; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA., McDaniel D; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; Biological Instrumentation Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Agrawal A; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA., Merricks EP; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Ragni MV; University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Leissinger CA; Department of Medicine, Louisiana Center for Bleeding and Clotting Disorders, Tulane University School of Medicine, New Orleans, Louisiana, USA., Stering AI; Walter Reed National Military Medical Center, Bethesda, Maryland, USA., Lieuw K; Walter Reed National Military Medical Center, Bethesda, Maryland, USA; Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA., Nichols TC; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Pratt KP; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Electronic address: Kathleen.pratt@usuhs.edu.

Publikováno v: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Dec; Vol. 22 (12), pp. 3415-3430. Date of Electronic Publication: 2024 Sep 02.

Pregnancy loss in individuals with von Willebrand disease and unspecified mucocutaneous bleeding disorders: a multicenter cohort study.

Autor: Skeith L; Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. Electronic address: laskeith@ucalgary.ca., James P; Department of Medicine, Queen's University, Kingston, Ontario, Canada., Kouides P; Mary M. Gooley Hemophilia Centre, Rochester, New York, USA., Uminski K; Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada; Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada., Duffett L; Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada., Jackson S; Division of Hematology, Department of Medicine, University of British Columbia Vancouver, British Columbia, Canada., Sholzberg M; Departments of Medicine and Laboratory Medicine and Pathobiology, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada., Ragni MV; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, USA., Cuker A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., O'Beirne M; Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada., Hews-Girard J; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Faculty of Nursing, University of Calgary, Calgary, Alberta, Canada., Rydz N; Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada., Goodyear DM; Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada., Baxter J; Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada., James A; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA; Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Garcia D; Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA., Vesely SK; Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Poon MC; Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada; Department of Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.

Publikováno v: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.

Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B.

Autor: Quon D; Orthopaedic Hemophilia Treatment Center, Luskin Orthopaedic Institute for Children, Los Angeles, CA., Jackson S; Providence Health Care, St. Paul's Hospital, Vancouver, BC, Canada., Alvarez-Román MT; Department of Hematology, University Hospital La Paz, Madrid, Spain., Khan U; Sanofi, Cambridge, MA., Casiano S; Sanofi, Cambridge, MA., Ragni MV; Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA., Rangarajan S; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 24; Vol. 8 (18), pp. 4751-4755.